Author: Belay Diagnostics

Posted Date:

March 24, 2026

Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study

Belay Diagnostics

March 24, 2026
Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)

Belay Diagnostics

February 18, 2026